Government Pharmaceutical Organization Partners with Sandoz for Biosimilar Production
Thailand’s Government Pharmaceutical Organization (GPO) has signed an MOU with Sandoz Thailand to collaborate on the production of high-quality biosimilar medicines.
On October 14, 2026, the Thai Government Pharmaceutical Organization (GPO) announced a strategic partnership with Sandoz Thailand, a subsidiary of the Swiss pharmaceutical firm, to advance the local production of biosimilar medicines. According to a report by Thai Post, the Memorandum of Understanding (MOU) was formalized at the Ministry of Public Health.
This collaboration aims to leverage Sandoz’s expertise in biosimilars—biological products highly similar to already approved reference medicines—to enhance the availability of high-quality, affordable treatments within Thailand. For residents and long-term expatriates, this initiative is significant as it signals a potential shift toward greater domestic self-sufficiency in specialized healthcare, which could eventually lower costs for complex medical therapies.
While the agreement marks a formal commitment to cooperation, several details remain to be confirmed. The specific timeline for the commencement of production, the list of targeted therapeutic areas, and the projected impact on retail drug prices have not yet been disclosed. As the project moves from the planning phase to implementation, further updates from the Ministry of Public Health are expected to clarify how this partnership will integrate into the national healthcare infrastructure.
